BioArctic AB (publ) announced that BioArctic AB and Eisai Co., Ltd., have entered into a research evaluation agreement regarding BAN2802, a potential new treatment combining BioArctic?s proprietary BrainTransporter? technology with an undisclosed Alzheimer drug candidate. At the end of the collaboration, Eisai will evaluate the data generated and decide if they chose to exercise an option to license BAN2802 for the treatment of Alzheimer?s disease.

BioArctic and Eisai have a long-standing collaboration dating back to 2005 regarding the development and commercialization of drugs for the treatment of Alzheimer?s disease. This collaboration has led to Leqembi® (lecanemab) ? the world's first approved drug shown to slow the progression of early Alzheimer's disease.

The new collaboration will build on the companies? joint knowledge in the field of Alzheimer?s disease. Costs for the research evaluation program will be shared and the program will evaluate what could be the next generation disease modifying treatment for Alzheimer's disease.